itp thesis 2022

ITP/IMA Thesis/Capstone Week 2022

Please join us for the   ITP/IMA Thesis/Capstone Week 2022   that is   happening this Tuesday, May 10 to Friday, May 13 (EST times). We have 4 sessions with about 10 -12 students presenting in each. The sessions break down as follows:

• Session 1: May 10, 10:00am – 12:00pm; 12:00pm - 3:00pm; 3:10pm - 6:10pm ET
• Session 2: May 11, 10:00am – 1:00pm; 1:45pm - 4:40pm ET 
• Session 3: May 12, 10:00am – 1:00pm; 1:45pm - 5:00pm ET 
• Session 4: May 13, 10:00am – 1:00pm; 1:45pm - 4:40pm ET 

The full presenter schedule is  HERE  and the Livestream Link can be found by clicking HERE .  Please feel free to join for as much or as little as you can.

Related Events

Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment

• James B. Bussel
• Christine A. Garcia

This article summarizes our approach to the diagnosis of immune thrombocytopenia (ITP), its secondary forms, and choice of second-line treatment options. We very briefly summarize first-line treatment and then utilize a case-based approach. We first explore persistent, chronic ITP in a younger female. We consider many possibilities beyond primary ITP e.g., hypogammaglobulinemia, chronic infection, and anemia, and how to approach their diagnosis and management. The journey continues throughout pregnancy and the post-partum period and eventually includes fourth-line treatment after a late relapse. We then consider an older male, emphasizing differences in diagnostic considerations and management. The focus is on initiation and continuation of second-line treatment, the pros and cons of each option, and briefly the impact of treatment choices related to the endemic presence of severe acute respiratory syndrome coronavirus 2. During the review of potential second-line treatment options, we also briefly touch upon novel treatments. Finally, there is a short section on refractory disease drawn from our previous extensive review published in February 2020.1 The clinical nature of the discussions, replete with figures and tables and with the interspersion of pearls regarding efficacy and toxicity at different ages and genders, will serve the reader in the management of “typical” adult patients who develop persistent and chronic ITP.

Introduction

Immune thrombocytopenia (ITP) is a complicated disease because of its heterogeneity and lack of diagnostic markers making selection of treatment difficult. Perhaps the most straightforward part of management is at presentation of ITP. If the platelet count is very low and no other findings are present, the worldwide consensus treatment is steroids. Whether dexamethasone, prednisone/prednisolone (prednis[ol]one), or intravenous (IV) methylprednisolone is used, the response rate and side effects are relatively predictable. IV methylprednisolone or dexamethasone increases the platelet counts faster and may have fewer side effects than have weeks of prednis(ol)one treatment. 2 Questions revolve around whether to add IV immunoglobulin (IVIG), and/or platelet transfusion. While the latter is rarely appropriate if there is serious bleeding and/or the diagnosis is unclear, an analysis based on medical records in the USA identified that as many as 25% of ITP patients receive platelet transfusion, 3 which is far too many.

The management of ITP becomes more complicated if other findings arise, if patients do not respond to steroids, or if patients continue to require treatment. Both the American Society of Hematology guidelines and an international consensus report emphasize that continued steroid use beyond 6 weeks is to be avoided. 4 , 5 Compliance with this strong recommendation entails earlier use of “second-line” therapy in patients with ITP, a practice already gaining traction. However, the definition of “early” remains fluid; “early” can be at 1 month of steroid treatment to allow discontinuation of steroids. “Early” can also be in the first 3 months when ITP is “newly diagnosed. 6 These ill-defined distinctions are one reason for substantial variation in the management of ITP. Another is the uncertainty of diagnosis. A third, the focus of this discussion, is how to select second-line treatment.

This review focuses on the initiation of second-line treatment reviewing the pros and cons of different agents utilizing a case-based approach by first exploring ITP in a young female and continuing throughout her pregnancy. The review then outlines diagnostic considerations and management in an older male with particular attention to secondary ITP in both patients.

Section I. A young female patient with immune thrombocytopenia: second-line treatment options

The patient’s history.

A 20-year-old female returns home from college. She notes heavier periods and easy bruising. Her internist sees that she is pale and has visible petechiae on her arms. Complete blood counts show mild anemia (hemoglobin 10.2 g/dL) and thrombocytopenia with a platelet count of 5x10 9 /L The internist sends her urgently to the emergency room concerned that she might possibly have leukemia. There is no hepatosplenomegaly or lymphadenopathy or other abnormal findings on physical examination.

Review of a peripheral blood smear reveals no blasts or abnormalities of other cell lines although her mean corpuscular volume is low (72 fL) and several of her very few platelets are large. She is diagnosed with ITP and given prednisone 1 mg/kg. Over the next few days, she has typical steroid-related side effects: feeling “a little crazy”, insomnia and abdominal pain. Her bruises and petechiae disappear, and her period ends. Her hematologist prescribes oral iron supplements and changes her prednisone to dexamethasone 40 mg daily for 4 days. Her steroid-related side effects worsen during the 4 days on dexamethasone 40 mg; however, she soon feels better with no further petechiae, bruising, or menstrual bleeding noted. Her platelet count normalizes to 147x10 9 /L and her hemoglobin improves to 11.2 g/dL. She begins checking her blood counts monthly. The improved complete blood count with a nearly normal mean corpuscular volume excludes bone marrow failure, and also thalassemia trait or microangiopathic hemolytic anemia. Similarly, the normal hemoglobin and neutrophil count do not suggest Evans syndrome. Her platelet counts remain in the normal range and her hemoglobin improves to the normal range. At her next visit, her platelet count has decreased to 80x10 9 /L. One month later, her platelet count is 28x10 9 /L with continued normal hemoglobin and infrequent small bruises. With her platelets trending downward, second-line treatment for her ITP is considered.

There is less urgency to consider secondary ITP or a missed diagnosis since she is doing well but at any change of management, it is good practice to re-evaluate. Below we consider some of the “ what if ” clinical scenarios for this young female.

What if the patient is persistently anemic despite iron supplementation?

If the mean corpuscular volume is low, consider workup for underlying thalassemia trait or iron deficiency with the latter being common in the setting of heavy menses. Iron replacement is not always straightforward; using oral replacement every other day may be equally effective as daily administration. 7 Resorting to IV iron may be important especially if oral replacement does not correct iron status and/or there are signs of a chronic inflammatory disease. If the mean corpuscular volume is high, bone marrow failure must be considered. There could also be pernicious anemia secondary to vitamin B12 deficiency or an autoimmune hemolytic anemia, such as Evans syndrome. Another possibility is microangiopathic anemia with thrombocytopenia, whether in the form of thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. In these cases, there would likely be increased reticulocytosis. While individually each of these conditions is rare, having one of many rare conditions would not be as surprising.

If heavy menstrual bleeding persists, a progesterone-based approach is superior to an estrogen-based approach in women with ITP as the former raises the platelet count. 8 While estrogen-based therapies are more commonly used in general practice for heavy menstrual bleeding, they might worsen ITP. 9 In contrast, progestational agents have previously been tried as treatment in ITP with good effect. Progesterone may be administered orally at a dose of 5-10 mg daily or medroxyprogresterone acetate (Depo-Provera) can be given intramuscularly once every 3 months but the latter may result in intermittent vaginal bleeding.

What if the immune thrombocytopenia is part of a larger spectrum of autoimmune disease?

Our patient’s immunoglobulins were normal, so she does not have common variable immunodeficiency (CVID) or IgA deficiency. Neither the diagnosis of CVID nor that of IgA deficiency requires a history of infections; in fact, there may be a history of autoimmunity, especially in a patient presenting with ITP, or allergy. Furthermore, the diagnosis of CVID is often not made until after the age of 30. 10 The IgG level does not have to be very low in cases of CVID presenting as ITP, which may account for the lack of infectious history in many of these patients. In cases of CVID, and possibly systemic lupus erythematosus with ITP, there may have been an episode of ITP years before treated with steroids, with the patient having gone into remission for years without any medication (Charlotte Cunningham-Rundles, personal communication ). Other immunodeficiency states are also associated with ITP, not all of which will include hypogammaglobulinemia. 11

Given our patient’s age and gender, it would not be surprising if she was positive for antinuclear antibodies and was developing systemic lupus erythematosus. A study from France suggests that hydroxychloroquine may be considered in an ITP patient positive for antinuclear anti-bodies. 12 Nor would it be surprising if her thyroid tests were abnormal, as thyroid disorders in young women with ITP are usually autoimmune. 13-16 In a young woman, there is a relatively high rate (as high as 5-10%) of abnormalities of thyroid function and this finding may be more frequent in women with ITP. The question remains of whether these conditions should be tested for in all patients or only if there are suggestive findings. If the patient is fatigued that would necessarily instigate an evaluation of underlying causes that would include hypothyroidism. Fatigue and depression are relatively common but poorly understood in ITP, 17 thus requiring comprehensive evaluation.

What if the immune thrombocytopenia is secondary to a subclinical viral infection?

Multiple viruses have been associated with ITP. In children, ITP is often thought to be a post-infectious sequela. There may also be an underlying viral disease which is asymptomatic and thus eludes detection. It remains unclear whether all patients with ITP should be screened for hepatitis C and human immunodeficiency virus; with the coronavirus pandemic, it might be appropriate to screen for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 18 Treatment of these three viral infections would alter ITP management. The primary treatment for both hepatitis C and human immunodeficiency virus would likely increase the platelet count. However, if hepatitis C has progressed to cirrhosis, the platelet effects of antiviral treatment may be limited. Another viral infection that could be subclinical is cytomegalovirus which might be revealed only by atypical lymphocytes and/or mildly elevated liver tests. Cytomegalovirus can worsen ITP in patients receiving immunosuppressive treatments because these agents will activate the cytomegalovirus and thus worsen the ITP making it more resistant to treatment. 19 , 20 Helicobacter pylori may “cause” ITP, but only in certain places, e.g., Japan and Italy, is searching for it at diagnosis of ITP routine and is its eradication a uniformly effective approach to ITP. 21

What if the patient has an inherited thrombocytopenia?

Our patient’s bleeding resolved in parallel with the improvement of her platelet count, which suggests that she does not have platelet dysfunction, as seen in Bernard-Soulier or Wiskott-Aldrich syndrome. Furthermore, she does not have any syndromic features consistent with an inherited thrombocytopenia. Review of her prior records revealed that she has had at least one prior normal platelet count.

The stability of her blood counts after initial treatment excludes cyclic thrombocytopenia which is an often-forgotten form of inherited thrombocytopenia. 22 There are very many forms of inherited thrombocytopenia and new ones seem to be discovered regularly. Certain features should suggest an inherited thrombocytopenia: 23 , 24 (i) other family members with thrombocytopenia; (ii) no past normal platelet count; (iii) too many too large platelets on a blood smear (not all inherited thrombocytopenias have macrothrombocytes but most do); (iv) features of a syndrome such as thrombocytopenia-absent radius syndrome; (v) failure to respond to treatment for ITP, such as IVIG and steroids: (vi) bleeding out of proportion to the platelet count e.g., Bernard-Soulier syndrome, Wiskott-Aldrich syndrome, RUNX-1 mutations; and (vii) a relatively stable platelet count. In the absence of an apparent specific syndrome, whole exome screening may be helpful, although this approach is effective in less than half of such cases. 25 Ideally this possibility would be explored in conjunction with an experienced geneticist. The importance of making a precise diagnosis is not limited to the management of the platelet count per se , but extends to the associated medical problems including a possible propensity to autoimmune conditions, malignancy, or bone marrow aplasia.

What if the immune thrombocytopenia is secondary to other blood disorders?

While chronic lymphocytic leukemia and myelodysplastic syndrome would be very unlikely in our patient given her young age, other clinical conditions could be present, such as autoimmune lymphoproliferative syndrome and systemic lupus erythematosus. It has not yet been decided which tests should be performed to search for specific conditions, particularly if there are not specific symptoms or conditions suggesting a particular entity. We assay immunoglobulin levels and do thyroid tests in our patients, as we certainly did in this young woman. Ideally in the future there would be an established panel of tests for patients with putative ITP which would explore inherited thrombocytopenias, bone marrow failure, secondary ITP, other diagnoses that could resemble ITP such as myelodysplastic syndrome, markers of the future course of the ITP, the degree of bleeding, and to which treatments the patient would respond best.

What is the optimal second-line treatment for a young female with immune thrombocytopenia?

There are numerous options that can be considered in this non-pregnant premenopausal female ( Table 1 )

Rituximab and other (generic) anti-CD20 monoclonal antibodies exert immunosuppressive effects by depleting B lymphocytes. This occurs uniformly in the blood and bone marrow but what happens to B cells in lymph nodes is not well-defined. Women under the age of 40 years with a less than 2-year history of ITP usually respond to rituximab, with the response rate and especially the “cure” rate being high. 26 If our patient and her hematologist opt for rituximab, she would receive four infusions of 375 mg/m 2 weekly for 4 weeks. If she has a good response, close monitoring may not be needed. While studies have not determined the optimal dose, 375 mg/m 2 once a week for 4 weeks is the most commonly used dosing regiman. The addition of dexamethasone to the rituximab may provide an extra “curative” effect via the former’s anti-plasma cell effect, although it also increases the risk of hypogammaglobulinemia. Administration of dexamethasone would reduce the first-infusion side effects of rituximab, and our patient could stop the steroid after one or two cycles if she does not tolerate it well instead of completing three cycles.

Table 1. Comparing second-line treatment options in non-pregnant premenopausal females.

It is prudent to check immunoglobulin levels to rule out CVID and a hepatitis B panel prior to starting rituximab. The risk of coronavirus disease 2019 (COVID) and delayed vaccination are in addition to other potential side effects such as first-infusion reactions, serum sickness, and even the very rare possibility of progressive multifocal leukoencephalopathy. If dexamethasone and rituximab are combined, there is a 10-20% possibility of developing hypogammaglobulinemia which may necessitate IVIG for a few months even in patients who start out with normal immunoglobulin levels. Combining this problem with the issue of the patient being unable to undergo vaccination for COVID reduces the benefit/risk ratio of rituximab treatment substantially, despite its curative potential. If the coronavirus pandemic wanes, this may be less of a consideration.

If treatment with rituximab is delayed too long in this woman, the chance of “cure” may be reduced. Her immunoglobulin levels are normal and she does not have hepatitis B surface antigen, so the risks of aggravated hepatitis B and hypogammaglobulinemia are less substantial. Lucchini et al. provide more information on the place of rituximab treatment in ITP. 27

Whether because of vaccination and/or infection, the current COVID pandemic is affecting ITP management and may have an impact on patients who are on second-line ITP treatment options. Guidelines on post-infection or vaccination ITP treatment are summarized in Table 2 . Our patient should be vaccinated against SARS-CoV-2 at least 5-8 weeks before initiating rituximab in order to have time to receive and fully respond to both doses of Moderna and Pfizer vaccines. It might be optimal to wait a little longer afterwards to sustain the vaccine effect. If the patient is not vaccinated prior to rituximab treatment, she will not be able to be vaccinated against SARS-CoV-2 for at least 6 if not 12 months; 28 this would also apply to a booster vaccination ( Table 2 ). The vaccination might affect her platelet count although she is not in a high-risk group which includes those who have had a prior splenectomy and/or five or more lines of previous ITP treatment. 29 There is limited information on the risk of developing severe COVID in ITP patients undergoing rituximab therapy. In CVID and especially agammaglobulinemia patients, the ability to clear the SARS-CoV-2 virus may be limited, and a patient may remain polymerase chain reaction-positive for weeks or even months.

Table 2. Considerations regarding severe acute respiratory syndrome coronavirus-2 and second-line treatments for immune thrombocytopenia.

On the one hand, rituximab with dexamethasone seems a good treatment option because, if she responds well to the four weekly infusions, she can be checked relatively infrequently afterward. On the other hand, the effects on response to SARS-CoV-2 vaccination are clinically significant. There appears to have been a marked decrease in rituximab use in ITP since the onset of the COVID pandemic.

Other immunomodulators

Previously, immunomodulatory agents were widely used second-line treatments, but drawbacks include the need to wait 1-3 months for the platelet count to increase, side effects (depending on the agent) such as hepatic toxicity, and the need to take these medications consistently long-term. 5 If a single agent is used, the risk of infection despite the immunosuppression seems very small, but for these agents, efficacy is less than 50%. This group is lumped together as if all agents are the same; it potentially includes mycophenolate mofetil, danazol, dapsone, azathioprine, cyclosporine, and cyclophosphamide.

Recently, a randomized controlled trial of steroids given with or without mycophenolate mofetil within 1 week of the diagnosis of ITP showed that the “cure” rate was higher in the combination arm. 30 One surprise was that quality of life was significantly lower among patients treated with the combination despite them having a better platelet response. Another surprise was that more than 50% of patients on the steroid-alone arm were cured despite a low rate of dexamethasone usage and that 27% of the patients were over 65 years of age. The study nonetheless highlighted the potential advantage of earlier use of second-line treatment.

There are at least 20 studies of danazol, almost all of which demonstrated a positive effect on platelet counts; this drug induces facial hair and acne and may be toxic to the liver. Dapsone, beyond an immunosuppressive effect, induces hemolysis which mimics IV anti-D; in patients with glucose-6-phosphate dehydrogenase deficiency, the hemolysis can be severe. Azathioprine has a long-standing history of use in ITP and a contributing safety base in pregnancy in patients taking it following kidney transplantation; it may cause hepatic toxicity in 1%. We reported on its combination with danazol, with good results in 13 of 17 difficult-to-treat patients. 31 Cyclosporine repolarizes cell membranes, which shuts down cell membrane pumps that extrude therapeutic agents from the cell. This may reinstate the effect of certain treatments e.g., steroids. Finally, cyclophosphamide can be given IV or orally. The best results appear to occur when using it IV in two or three infusions. 32 Mechanistic information supporting the use of cyclophosphamide is that it has anti-plasma cell effects and that it spares megakaryocytes and platelets. Cyclophosphamde does, however, have well-known substantial side effects: hematuria, bladder fibrosis, immunosuppression, and nausea and vomiting.

Thrombopoietin receptor agonists

Another option for second-line therapy would be a thrombopoietin receptor agonist (TPO-RA). The primary advantages of these drugs are the high response rate and low likelihood of induction of malignancy or other irreversible toxicity. The primary toxicity is development of venous and arterial thrombosis. If our young female patient were on birth control, there may be an added risk of thrombosis.

There are three TPO-RA currently available in the USA and

Western Europe: romiplostim, 33 eltrombopag 34 and avatrombopag; 35 their efficacy and toxicity have been outlined in a recent review, including discussion of class effects such as headache, myalgia, and thrombosis. 36 The mechanisms of effect of these agents differ by where they bind to the thrombopoietin receptor, in RNA upregulation of transcription factors by romiplostim and eltrombopag, 37 and by the essential role of intracellular iron chelation by eltrombopag. 38 The clinical importance of these mechanistic differences is “confirmed” by “switch studies” in which one of romiplostim or eltrombopag was effective when the other was not. 39 , 40 Recent studies demonstrated that switching from one of these two TPO-RA to avatrombopag was also often effective. 29 , 41 Toxicity and efficacy do not differentiate the three agents substantially, although one article suggests that romiplostim maintains efficacy at higher endogenous thrombopoietin levels than does eltrombopag 29 and eltrombopag is thought to be associated with higher rates of transaminitis. 34 , 36

Eltrombopag. Eltrombopag is an oral TPO-RA which requires a very empty stomach ideally 2 hours before and after taking it, which is intimately related to its requirement to chelate intracellular iron as an integral part of its mechanism of effect. 38 If eltrombopag has chelated calcium or iron during ingestion, it cannot chelate intracellular iron and will, therefore, be ineffective. Liver function tests must be monitored in patients taking eltrombopag, as hepatotoxicity is considered common (1-10%) and 3% of adults and children cannot tolerate eltrombopag for this reason. 36

Romiplostim. Because romiplostim is injected subcutaneously weekly, there are no issues of absorption or doubts about compliance. There may be more cycling of the platelet count as compared to that with the oral TPORA, likely because of romiplostim’s weekly instead of daily administration. As with all the TPO-RA, making small changes in dosing will limit the likelihood of cycling. Development of antibodies, neutralizing and non-neutralizing, to romiplostim is more common in children than in adults; 44 however, these antibodies have surprisingly little effect on clinical efficacy for reasons that are not clear. Myalgia may be more common with romiplostim. As of writing, romiplostim can be self-injected by patients in Europe but not in the USA.

Avatrombopag. Avatrombopag, a second oral TPO-RA, has the least data describing its use. It is taken once daily using only tablets of 20 mg with dose ranges from 20 mg by mouth once a week to 40 mg (2 tablets) daily. There are very limited data on long-term usage. In one study, avatrombopag was associated with a 16.5% incidence of thrombosis but this was likely an artifact resulting from the small numbers of patient. 42 Two recent studies testified to the effect of avatrombopag in patients not responding to romiplostim and/or eltrombopag. 29 , 41 It is recommended that this TPO-RA is taken with food so that its absorption is more consistent.

There is much to recommend the use of a TPO-RA in our young woman. 43 , 44 There is no reason to suspect that such an agent would have an adverse impact on the clinical course of COVID if an infection were to occur although there may be an additive risk of thrombosis. 29 In the COVID pandemic, the oral agents would be preferred over romiplostim to lessen exposure to SARS-CoV-2 secondary to weekly attendance at an outpatient department. Local laboratory counts and virtual visits lessen this risk for patients; home nursing visits for injections would do the same.

Fostamatinib

Fostamatinib is a first-in-class, orally active spleen tyrosine kinase (Syk) inhibitor indicated for the treatment of ITP. The primary studies underestimated its efficacy, probably because the median duration of ITP in the trial population was more than 8 years and in 47% of patients a TPO-RA had failed. 45 , 46 While the starting dose is 100 mg twice daily, 89% of responders increased to 150 mg twice daily. Long-term use and in vitro experiments have suggested that fostamatinib is anti-thrombotic but not prohemorrhagic because blocking Syk reduces signaling via the C-type lectin-like type II transmembrane receptor (CLEC2) and glycoprotein VI (GPVI) pathways. These two pathways have less redundancy in thrombosis than in control of bleeding. Fostamatinib is also thought to be anti-inflammatory and potentially useful in COVID, independently of any platelet effects. 47 On the other hand, of all approved second-line agents for ITP, it may be the least tolerable. It increases blood pressure in most recipients and there are relatively frequent gastrointestinal effects, including nausea with very occasional vomiting and the development of diarrhea; 5% of patients may develop transaminitis. There has not been evidence of increased frequency or severity of infections in association with fostamatinib use even though Syk is present in macrophages as well as in B cells and in other cells.

Splenectomy

The American Society of Hematology guidelines and international consensus report recommend that splenectomy be delayed to at least 1 year after the diagnosis of ITP, since the rate of resolution of ITP within the first 1-3 years of disease appears substantial even in adults. 4 , 5 Laparoscopic splenectomy is infrequently complicated by perioperative problems; response rates are initially 80% which relapse reduces to 60%. Late relapse beyond 2 years after splenectomy is very uncommon. Whether delaying splenectomy reduces its efficacy is a concern; a recent study from France 48 suggests that efficacy is maintained, and some patients responded better to TPO-RA after splenectomy.

There are long-term risks of adverse effects of splenectomy which are clinically significant, including not only overwhelming sepsis but also thrombosis, especially stroke. The risk of sepsis is based on less efficient blood stream phagocytosis and is exacerbated by low antibacterial antibody levels. Pneumococci are a more frequent cause of post-splenectomy sepsis than all other infections combined. 49 Following splenectomy, individuals also have an elevated risk of infections by encapsulated Gramnegative pathogens, e.g., Capnocytophaga canimorsus and Bordetella holmesii , as well as intraerythrocytic parasites, such as malaria and Babesia , as noted in a recent review of post-splenectomy infections. 50

Providing patients appropriate and timely immunization for pneumococci, Hemophilus influenzae B , and meningococcus, antibiotic prophylaxis, education, and prompt treatment of infection mitigates this risk; 51 when to repeat pneumococcal and other vaccinations remains unclear. While vaccination appears more effective if given at least 2 weeks prior to splenectomy, vaccination can be administered after splenectomy if there is not time before the splenectomy or if vaccination would likely be ineffective because the patient is receiving high-dose immunosuppression or has recently received rituximab.

The risk of post-splenectomy thrombosis was not initially appreciated. Population studies using a Danish registry identified this risk, particularly with regard to stroke, with confirmation in other populations, e.g., the Nurses’ Health Study. 52 Splenectomy for hemolytic anemias has been complicated by pulmonary hypertension, with mitigation by partial splenectomy and reduction in the use of splenectomy. Partial splenectomy may “hit the sweet spot” by reducing red blood cell phagocytosis but maintaining enough phagocytosis to prevent pulmonary hypertension and sepsis. The apparent absence of pulmonary hypertension after splenectomy for ITP suggests that partial splenectomy, like splenic embolization and radiation, is very rarely if ever used.

How we treated the young woman with immune thrombocytopenia

As this woman could not taper her prednisone successfully, still had bleeding, and had a platelet count <20x10 9 /L, she met the criteria to receive a second-line treatment. After the considerations provided above and with her primary ITP, she opted for a TPO-RA which was based on her fear of COVID and need for vaccination and being in the first year of her disease. She chose to reserve rituximab, fostamatinib and immunosuppressives. She took a TPO-RA for a year and then was gradually able to discontinue it. She maintained a platelet count of 6090x10 9 /L on no treatment for several years without manifestations of bleeding. She was not troubled by fatigue or heavy menstrual bleeding.

Section II. Immune thrombocytopenia in pregnancy

Years later, our patient becomes pregnant.

What are the treatment considerations for our patient during pregnancy?

As ITP is common in women of reproductive age, it is not surprising that it may complicate the course of pregnancy. For pregnant women with known ITP, management changes throughout the course of pregnancy. 53 Figure 1 reviews treatment options available during each trimester, leading up to delivery and the post-partum period. In the first trimester of pregnancy, platelet counts may spontaneously increase, apparently because of the increased progestational hormones in the first trimester. 54 For this reason, relatively few women with ITP require treatment in the first trimester, which is fortunate from a teratogenic point of view. Risk of cleft palate from steroid use in the first trimester appears to be small.

In the second and especially third trimesters, platelet counts decrease even in healthy women without ITP, resulting in “gestational” thrombocytopenia. 55 Three large series suggest that the prevalence of gestational thrombocytopenia at the end of pregnancy is between 6.6% and 11.6%. 56-60 This has been attributed to increased volume of distribution in the later stages of pregnancy as well as “consumption”. Recently, work from China presented at the 2021 European Hematology Association Congress hypothesized that very high estradiol levels towards the end of pregnancy inhibit platelet production. 61 While requiring confirmation, this hypothesis fits with both platelet counts falling and cases of ITP in pregnancy becoming progressively more difficult to treat with steroids and IVIG. Fortunately, there is rarely clinically significant bleeding in pregnant women with ITP unless the platelet counts become very low; one exception may be subchorionic hematomas.

Figure 1. Treatment options for immune thrombocytopenia during pregnancy, leading up to delivery, and in the post-partum period. IVIG: intravenous immunoglobulin; TPO-RA: thrombopoietin receptor agonist; ITP: immune thrombocytopenia.

Table 3. Considerations regarding treatment options for immune thrombocytopenia during pregnancy.

Tranexamic acid can be used after delivery to reduce blood loss in this period and thus reduce blood transfusion requirements. The risk of postpartum thrombosis seems very low, although pulmonary emboli have been reported in two cases. 62

Steroids in pregnancy

The standard treatments for ITP during pregnancy are steroids and IVIG ( Table 3 ) which are the most widely used and felt to be the safest. The prednis(ol)one recommendation for ITP in pregnancy, because of the limited duration of anticipated treatment, is relatively low-dose prednisone (e.g., 10-20 mg daily) based on targeting a platelet threshold of 20-30x10 9 /L. Prednis(ol)one often exacerbates physiological changes of pregnancy e.g., hyperglycemia, hypertension, and fluid retention; dexamethasone is to be avoided because of its fetal effects. If this lower dose of prednisone is successful, it avoids the risks of long-term high-dose steroids for the mother. Little to no prednisone enters the fetus because of placental β-11-hydroxylase. 63

WIntravenous immunoglobulin in pregnancy

IVIG is effective; however, it must be given often e.g., biweekly so steroids are the recommended treatment. One study suggests that both steroids and IVIG are slightly less effective in pregnant women. 64 Overall, whether the efficacy of IVIG and prednis(ol)one in pregnancy is maintained becomes more important later in pregnancy. Patients who are difficult to treat require higher and higher doses of prednisone and more and more frequent IVIG dosing as pregnancy progresses.

The treatment of fetal and neonatal alloimmune thrombocytopenia has provided safety information that may be extrapolated to ITP. ‘Aggressive intrapartum treatment’ exceeds that of the treatment of ITP by including IVIG 1-2 g/kg/week and prednisone 0.5 mg/kg/day for many weeks. The apparent safety of these very high doses helps to assuage concerns regarding their use in ITP. 65 Even with less severe ITP, preparing for safe delivery often involves intervention to undergo epidural anesthesia, for which the platelet count is often “required” to be greater than 80x10 9 /L. The requirements for spinal anesthesia may not be as strict and are more variable than they are for epidural anesthesia. Even in a patient who responds well to IVIG and prednis(ol)one combination treatment, a platelet count of 80x10 9 /L or higher is often achieved for only 2-5 days. If these treatments are relied upon, scheduling elective delivery is crucial so that administration of IVIG can be timed to achieve its optimal effect. The patient could either undergo a Caesarian section or have her membranes ruptured so she enters labor at the desired time. An amniocentesis may be required to assess fetal lung maturity.

Rituximab in pregnancy

In one study of 231 pregnancies with maternal exposure to rituximab for treatment of autoimmune cytopenias and other autoimmune disease, few neonatal infections were seen among the exposed neonates. 66 Hypogammaglobulinemia will not be present at birth if the mother does not herself have low IgG levels; however, it may manifest at 2 to 4 months of age if there is a persistent absence of infant B cells. Women are encouraged to avoid pregnancy for more than 4-6 months after rituximab exposure to prevent transmission of the rituximab to the fetus. 66 As shown in Figure 1 , we believe that rituximab can be used in patients who do not respond well to steroids and IVIG.

Intravenous anti-D, azathioprine, cyclosporine, and splenectomy in pregnancy

Eight patients were treated with IV anti-D (WinRho) with reasonable efficacy and fetal safety; 67 no cases of neonatal anemia or hyperbilirubinemia were seen. Azathioprine has been extensively used in women who have undergone renal transplantation and become pregnant. 68 The registry of these patients suggested that azathioprine is relatively safe during pregnancy, but azathioprine takes 1-3 months to increase the platelet count. Infants of mothers taking azathioprine are noted to have an increased prematurity rate, lower birth weight, and intrauterine growth restriction; no malformations were seen. Immune impairment was reported in some exposed infants. 69 The effects of cyclosporine in pregnant women with ITP appear to be like those of azathioprine: reasonably effective, slow in onset, and with limited fetal risk. Experience of cyclosporine use in pregnant women has also been gained in the post-transplantation setting. 70 Mycophenolate is contraindicated in pregnancy. 71 If splenectomy is required, it is recommended that it be performed in the second trimester because the risk to the fetus is less than in the first trimester and the size of the uterus will be less obstructive than in the third trimester. Experience consists of isolated case reports.

Thrombopoietin receptor agonists in pregnancy

A major recent development affecting ITP in pregnancy is the use of thrombopoietin agents. Three sets of evidence for the use of thrombopoietin agents in pregnancy exist beyond scattered case reports. One study used recombinant human thrombopoietin (rhTPO, available in China) and evaluated 33 pregnancies in 31 women with ITP in pregnancy who did not respond to or relapsed after an initial response to prednisone. 72 Seventy percent of the women responded to rhTPO with an increase in the maternal platelet count and no overt maternal toxicity. Importantly, the babies, followed until 1 year of age, did not have any identified side effects of rhTPO treatment. A follow-up compilation of ITP cases explored 13 pregnancies in 12 women, including one who delivered a pair of twins, in whom a TPO-RA was used. 73 Usage of TPORA was divided equally between eltrombopag and romiplostim and both agents appeared effective and safe. Third, a safety surveillance program report of use of romiplostim in 186 women with ITP who received romiplostim during pregnancy indicated that in over 50 pregnancies with known pregnancy outcomes and in over 50 pregnancies with known birth outcomes, romiplostim appeared safe. 74 There were 12 births with thrombocytopenia requiring treatment, consistent with the maternal ITP; all were discharged home with eight having their thrombocytopenia resolved pre-discharge. Although limited by incomplete information, 75 women were exposed to romiplostim in the first trimester because of having been treated with romiplostim at the time they became pregnant. From the over 150 pregnancies for which any data were available, five infants had some kind of adverse finding: one had cytomegalovirus infection, one had unilateral inguinal hernia, one had a single umbilical artery with no other findings reported, one child was normal at birth but at the age of 2 was identified as autistic and one infant, whose mother received only one dose of romiplostim in the third trimester, had trisomy 8.

In summary, according to three reports of the use of three different thrombopoietin agents in pregnancy, these drugs appear to be safe as a class with no information available for avatrombopag, very limited information for eltrombopag, and considerable safety but little efficacy information for romiplostim. While efficacy is likely to be preserved in the mother, it is not known whether transplacental passage of these agents increases the neonatal platelet count. Our conclusion is that a thrombopoietin agent should only be used when the benefit outweighs the risk. However, if a thrombopoietin agent is considered in the third trimester, the available data strongly suggest that romiplostim is safe for the fetus ( Figure 1 , Table 2 ).

After scheduled vaginal delivery, our patient does well as does her baby. She breastfeeds but her newborn has persistent thrombocytopenia with platelet counts down to 30 x 10 9 /L. She is prompted to stop breast feeding and, upon doing so, the infant’s platelet count rapidly increases to normal. The mother’s platelet count also return to its pre-pregnancy level and all treatment can be stopped.

Section III: Second-line treatment of immune thrombocytopenia in an older male patient

What if instead of a young woman in her early 20s, our patient is a 63-year-old male.

This patient is generally healthy but slightly overweight and had his gall bladder removed without incident 6 years ago. He has taken daily losartan, atorvastatin, and a baby aspirin for several years. Upon presentation with bruises, petechiae and profuse bleeding from his gums when he brushes his teeth, he is told to stop his aspirin. He is given dexamethasone 40 mg/day for 4 days and a single dose of IVIG 1 g/m 2 /kg because of the aspirin. His platelet count increases dramatically within 2 days.

What diagnostic considerations are important here? First, as with the young woman, ITP must be distinguished from other thrombocytopenias; these are common in the elderly but different from those in a young woman. Autoimmune diseases such as systemic lupus erythematosus are much less likely, as are inherited thrombocytopenias. CVID is possible at any age but in addition to assaying serum immunoglobulins, serum protein electrophoresis to look for monoclonal proteins is appropriate. Other congenital immunodeficiency diseases are less likely, but lymphoproliferative diseases are more common. Chronic lymphocytic leukemia and non-Hodgkin lymphoma are both B-cell diseases associated with ITP. A blood smear may show too many small mature-looking lymphocytes; if T- and B-cell studies are performed, they would reveal too many B cells. Clonal hematopoiesis of indeterminate potential might occur but it is not clear what this condition would portend assuming the clonal cells do not reflect an overt malignancy. Preliminary information suggests that clonal T-cell populations may mediate refractoriness. 75 Ultrasound and/or computed tomography scans to look for malignancy may be indicated.

An important cause of thrombocytopenia in elderly patients is myelodysplastic syndrome. A bone marrow examination is necessary to diagnose this condition. Typically, marrow will be hyperplastic, but marrow cells will be undergoing apoptosis and not producing mature blood cells and reveal dyspoiesis. Diagnostics have improved remarkably as has clinical discrimination of different subtypes of myelodysplastic syndrome. Nonetheless. cases of myelodysplastic syndrome early in their evolution may be difficult to distinguish from “difficult” ITP. 76

Drug-induced thrombocytopenia is a possibility since older patients may be taking more medications. Limited laboratory testing is available to demonstrate that thrombocytopenia is drug-induced. Diagnosis generally relies on recognizing medications likely to cause thrombocytopenia; one approach is to change medications if any are newly initiated. Viral infections could also occur in this population e.g., hepatitis C, cytomegalovirus.

Patients over the age of 60 are thought to have a higher likelihood of fatal and non-fatal serious bleeding compared to younger patients ;77-79 recent studies of intracranial hemorrhage have supported earlier findings demonstrating a higher risk in those above 60 years of age. Thus, it may be appropriate to pursue an aggressive approach in this patient, such as the addition of IVIG to steroids.

Which second-line treatment is optimal for a 63-year-old male?

Rituximab in an older male.

In this case of ITP, the older man has a reasonable likelihood of a response but, even if he responds well, his response will very likely last only 6-12 months. The chance of a long-term (>1 year) response is low. Furthermore, as discussed previously, after rituximab it would not be possible to vaccinate the patient against SARS-CoV-2, which is important since this 63-year-old is in a high-risk group and would benefit from boosters. As indicated, there is a 10-20% possibility of developing significant hypogammaglobulinemia when the combination of dexamethasone with rituximab is used. 26 A good initial response followed by the expected relapse would allow rituximab to be reused, but it remains unlikely to lead to a cure 80 and the probability of hypogammaglobulinemia occurring is thought to increase with repeated use.

Splenectomy in an older male

Splenectomy is used even less in this age group, since efficacy is lower, and the risk of side effects is higher. The results of splenectomy are less successful in older patients with ITP, but there is no clear age at which this effect occurs. 81 In addition, there may be a higher risk of peri-operative complications and post-splenectomy thrombosis in this older patient. One could take a risk-based approach to splenectomy for this 63-year-old by considering the comorbidities and proceeding if he has few to no comorbidities.

Thrombopoietin receptor agonists in an older male

Another second-line therapy is a TPO-RA. The primary advantages remain the high response rate and the low likelihood that there will be major side effects although venous and arterial thrombosis would be the primary concerns in this older man. It is important to fully assess the risk of thrombosis looking at risk factors such as obesity, family history, and personal history. 53 The use of thrombopoietin agents would be similar in both patients and is described in the package inserts and a recent review. 36

If romiplostim is chosen, we would initiate treatment with 3 mg/kg/week and increase by 2 mg/kg/week until the platelet count rises above 30-50x10 9 /L. In more practical terms, this could mean whole vials of 250 and 500 micrograms which are almost universally available; if smaller and larger vial sizes are/become available this would allow more precise weight-based dosing. If a sufficient platelet count is achieved, it is important not to change romiplostim doses too quickly, i.e., not more than 1 mg/kg/week. This minimizes cycling of platelet counts and prevents them from going too high or falling too low. If the platelet count goes very high (with any of the 3 TPO-RA), do not withhold the dose, but decrease it by 1 mg/kg (or equivalent); several days of aspirin can be given if there is concern of thrombosis.

If eltrombopag is chosen, the starting dose is 50 mg by mouth daily; lower doses might be required in East Asian patients. If the count does not increase sufficiently within 1-2 weeks, increase the dose to 75 mg daily. If the count increases too much, decrease the dose to 25 mg daily. The maximum change would be 25 mg/daily once a week. If none of the doses allows for a stable count of 50-100x10 9 /L, then alternating doses might be preferred e.g., 50 mg on odd days and 75 mg on even days. As discussed, eltrombopag must be taken on an empty stomach. In our experience, the best approach is to eat dinner, not eat after the end of dinner and then take the eltrombopag with water at bedtime, at least 2 hours after dinner. If this gentleman urinates every night, this could be a time to take eltrombopag. If avatrombopag is chosen, the starting dose is 20 mg daily. The dose could be adjusted to as high as 40 mg daily or as low as 20 mg on one day per week. There is only one size of avatrombopag tablet, i.e. 20 mg. The tablet is taken once daily and there are no dietary restrictions. As with the other agents, dose changes should be limited in magnitude and not performed more often than weekly.

With all three agents, it is not clear how/when to taper and attempt to discontinue treatment. A recent study demonstrated a greater than 50% successful discontinuation rate when at least 2-3 months of stable TPO-RA dosing, no bleeding, and a platelet count >100x10 9 /L were required for the discontinuation attempt. 82 Patients were on romiplostim a median of 12 months before tapering; the doses administered were higher than normal to obtain stable counts >100x10 9 /L. The tapering protocol was at 2-weekly intervals for a total of not more than 2 months of tapering. It remains unclear how often a patient who has required a thrombopoietin agent for 2 or more years will be able to discontinue treatment. Other studies have suggested an approximately 20-25% rate of successful discontinuation in the first year.

Fostamatinib in an older male

If this patient were at particular risk of thrombosis, fostamatinib might be a particularly good option. Otherwise, in general practice, it is usually reserved for patients who have failed to respond to thrombopoietin agents.

With many second-line agents, there are various treatment options and courses depending on individual responses, relapses and potential complications with each agent, as demonstrated in Figure 2 .

Figure 2. Second-line treatment options for immune thrombocytopenia and possible treatment courses. TPO: thrombopoietin; R1, R2, R3, R4: first, second, third and fourth weekly dose of rituximab; COVID: coronavirus disease 2019; ITP: immune thrombocytopenia; BID: bis in die.

Section IV: Third-line therapy for immune thrombocytopenia and beyond

What happens if the thrombopoietin agent used in the two patients does not work or at least cannot be tapered.

In the case of the young woman, the platelet count remained less than 20x10 9 /L and the young woman had heavy menses, bruising and nosebleeds. The now 26-year-old woman opted for rituximab. She had a long-term response but unfortunately relapsed after 4 years. She considered repeating the rituximab and undergoing splenectomy but opted to try a different thrombopoietin agent since she was not planning another pregnancy in the immediate future. Previously she used eltrombopag so she now tried avatrombopag. On a dose of 20 mg/day she was able to maintain an adequate platelet count and is very slowly tapering her dose. This choice was consistent with evidence that not responding well to one TPO-RA does not preclude good response to another.

Our older, male patient, given his continued bruising and minor nosebleeds, was afraid of major bleeding; he also felt very tired even though he was not anemic. The now 64-year-old man opted to try rituximab since avatrombopag did not work well for him. He received the standard dose of rituximab with dexamethasone. He responded which a platelet count of 60x10 9 /L by 6 weeks after initiating treatment; however, his count started to fall monthly down to 30x10 9 /L. He and his doctor decided to initiate mycophenolate mofetil and he began with a dose of 500 mg twice daily and then increased to 1000 mg twice a day. He tolerates this treatment well and his platelet counts remain around 40-50x10 9 /L.

Thus, both patients needed treatment. Some patients with low (not very low) platelet counts who have no bleeding or other issues e.g., need for anticoagulants or fatigue, may not require treatment. Avoiding treatment is always optimal if this does not jeopardize quality of life.

What if none of the obvious options (thrombopoietin agents, rituximab, splenectomy) helps and no single treatment, including fostamatinib and mycophenolate mofetil is effective?

It is difficult to predict what approach will be effective in these “refractory” patients. If a patient has been on too low a dose or for too short a period, it may not be clear that a given medication will not be helpful.

The approach to difficult-to-treat patients, such as these examples, is discussed at great length in our review of refractory ITP and in another recent review. 1 , 83 The major principles are: (i) spend time reconfirming the diagnosis; reconsider all options if response to treatments of ITP is absent or very limited: (ii) do a complete bone marrow examination, unless one was performed recently, with aspirate, biopsy, flow cytometry, and cytogenetics; (iii) if a treatment is ineffective, continue the treatment and add another treatment initiating combination therapy. In our opinion, this is preferable to discontinuing the ineffective treatment and starting another one; (iv) if indeed the case is refractory ITP, combination approaches are often better than single treatments. Including treatments with different mechanisms of effect is useful; however, there are situations in which two agents targeting the same mechanism are effective such as combining IVIG and IV anti-D; 31 and (v) when using combination treatments, it would be ideal to not give maximum doses and to select agents with differing toxicities. If an adverse event requiring a change in treatment occurs, it is then easier to choose the agent to stop and/or replace. In our review of published reports, 1 a TPO agent was often a crucial component of combination treatments.

In difficult patients, the inability to define the pathogenesis in most cases makes the treatment selection blind. Fortunately, multiply refractory patients for whom no treatment seems to bring their platelet count up at all are very rare. More commonly at least one treatment will transiently increase the platelet count. This minimizes the chance of serious bleeding and creates an approach for ongoing management, although continued steroid overuse must be avoided.

Section V. Agents currently under study

What are the experimental agents which are likely to be available in the future.

Various experimental agents for ITP are being studied and other drugs, currently used for other conditions, are now undergoing trials in ITP. It is uncertain whether, and if so in what context, any or all these agents will ultimately have a major role in the management of ITP. On the one hand, they could be more effective and less toxic than currently used agents and have specific areas of efficacy based on their unique mechanisms of effect. On the other hand, they might be redundant, have toxicities, and not provide substantial additional value.

FcRn inhibitors

The putative mechanism of effect of FcRn inhibitors is reduction of antiplatelet IgG levels by inhibition of “normal” IgG recycling. IgG levels fall dramatically with FcRn inhibition, and it is thought that the IgG anti-platelet antibody levels fall at least as much, resulting in less platelet destruction and greater platelet production. Efgartigimod and rozanolixizumab have gone through phase II studies; the results were published in 2020 and both studies demonstrated more than 50% acute platelet responses. 84 , 85 Both agents are in ongoing phase III trials which, like many studies, were slowed by the COVID pandemic. Since FcRn inhibition does not lower IgA and IgM levels nor does it affect T-cell or macrophage function, trials have not been complicated by the development of infections despite very low IgG levels being reached. Nonetheless, there is concern that IgG levels below 200 mg/dL (lower limit of normal: 639 mg/dL) may be dangerous. With one FcRn inhibitor, albumin levels were lowered, and cholesterol increased; FcRn also recycles albumin.

Active studies of FcRn inhibitors include treatment of myasthenia gravis, pemphigus vulgaris, hemolytic disease of the fetus and newborn, and antibody-mediated neurological diseases. In the phase III studies, the FcRn inhibitors are being administered weekly by subcutaneous administration with the goal of eventual home administration.

Bruton tyrosine kinase inhibitors

The most widely used Bruton tyrosine kinase (BTK) inhibitor is ibrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma with excellent results in treating these entities; anecdotally, several thrombocytopenic patients with chronic lymphocytic leukemia had substantial platelet improvements. Thus, it was natural to think of BTK inhibition for B-cell diseases like ITP. However, ibrutinib was found to lead to serious bleeding in about 1% of cases, an effect that was subsequently suggested to be caused by inhibition of collagen-platelet interactions. Newer BTK inhibitors, e.g., rilzabrutinib, designed to allow normal platelet function for patients with ITP, have been effective in ITP in phase II trials, with a 50% response rate seen at the top dose, 400 mg twice a day. 86 As was seen in trials with fostamatinib and FcRn inhibitors, the patients enrolled have been heavily pretreated with long-term histories. It is highly likely that BTK inhibitors will inhibit response to SARS-CoV-2 vaccination.

Complement inhibitors

Studies of complement pathway inhibitors in ITP would have begun years ago if the cost of the Alexion anti-C5 monoclonal antibody (eculizumab) had not been so enormous. Early results of C 1 S inhibition are impressive but still preliminary. This strategy has yielded good results in cold agglutinin disease, demonstrating its biological effect on the complement system which is translated into clinical hematologic efficacy.

Conclusions

What would we have liked to have been able to offer our two patients with immune thrombocytopenia.

First, it would have been nice to have been able to predict their course including many factors: risk of bleeding, likelihood of chronicity, which treatments would be most effective, and which most toxic.

Second, it would have been nice to have a curative but non-toxic treatment to offer. We discussed the use of rituximab in a younger woman as there is good likelihood of cure in a patient of this age and gender. But in other patients, there is very little likelihood of cure and in her case, vaccination for SARS-CoV-2 was a problem. This leaves splenectomy which is remarkably effective; recent work suggests that it remains effective even in patients who have been treated with thrombopoietin agents. 48 Why are patients so unwilling to undergo splenectomy? Perhaps the primary reasons are the inability to know whether a patient will get better on their own, whether the splenectomy will be successful, and the irreversibility of it. Furthermore, post-splenectomy risks of sepsis and thrombosis continue lifelong. In the future, use of combinations of agents (dexamethasone and rituximab, steroids and mycophenolate mofetil, dexamethasone and eltrombopag, or others) within 1 week of diagnosis may provide a higher level of cure and justify the extra expense and higher risks of these interventions.

Finally, treatment selection could be more rational if data were provided by randomized, controlled trials comparing agents and regimens. To date, all the randomized controlled double-blind trials of second-line agents have involved comparison of a treatment to placebo. We are not aware of any trials comparing one second-line agent to another, although Chinese hematologists have recently compared a given agent to the same agent plus a second agent. Examples include rituximab with and without thrombopoietin, and dexamethasone with and without eltrombopag. More of these studies are urgently needed.

In summary, it is not possible to have a “one size fits all” approach to ITP. Rather we have tried to emphasize that individualizing treatment is important and should include shared decision-making. The optimal choices vary with gender and age and the COVID pandemic has an impact as well. As additional information is accrued, management in certain situations may be clarified but there is a long way to go to achieve for ITP what we all take for granted in the evidence-based management of leukemia. 87

• Received February 23, 2022
• Accepted June 7, 2022

Correspondence

J.B. Bussel [email protected]

Disclosures

JBB is a consultant or on an advisory board for Amgen, Novartis, Sobi, Rigel, UCB, Argenx, Sanofi, Astra-Zeneca, Pfizer, and CSL-Behring; and is a member of a Data and Safety Monitoring Board for UCB, CSL-Behring. CAG has no conflicts of interest to disclose.

Contributions

JBB and CAG wrote and edited the manuscript and both agreed to its submission for publication.

• Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020; 135(7):472-490. https://doi.org/10.1182/blood.2019003599 PubMed PubMed Central Google Scholar
• Mithoowani S, Gregory-Miller K, Goy J. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016; 3(10):e489-e496. https://doi.org/10.1016/S2352-3026(16)30109-0 PubMed Google Scholar
• Goel R, Chopra S, Tobian AAR. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019; 59(1):169-176. https://doi.org/10.1111/trf.15069 PubMed Google Scholar
• Neunert C, Terrell DR, Arnold DM. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. https://doi.org/10.1182/bloodadvances.2019000966 PubMed PubMed Central Google Scholar
• Provan D, Arnold DM, Bussel JB. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22):3780-3817. https://doi.org/10.1182/bloodadvances.2019000812 PubMed PubMed Central Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11):2386-2393. https://doi.org/10.1182/blood-2008-07-162503 PubMed Google Scholar
• VanderMeulen H, Sholzberg M. Iron deficiency and anemia in patients with inherited bleeding disorders. Transfus Apher Sci. 2018; 57(6):735-738. https://doi.org/10.1016/j.transci.2018.10.015 PubMed Google Scholar
• Maric D. Effect of the successive application of estradiol and progesterone on the number of blood platelets of the rabbit. C R Seances Soc Biol Fil. 1960; 154:1865-1866. Google Scholar
• Onel K, Bussel JB. Adverse effects of estrogen therapy in a subset of women with ITP. J Thromb Haemost. 2004; 2(4):670-671. https://doi.org/10.1111/j.1538-7836.2004.00644.x PubMed Google Scholar
• Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol. 2020; 11:149. https://doi.org/10.3389/fimmu.2020.00149 PubMed PubMed Central Google Scholar
• Grace RF, Lambert MP. An update on pediatric immune thrombocytopenia (ITP): differentiating primary ITP, IPD, and PID. Blood. 2021. https://doi.org/10.1182/blood.2020006480 PubMed Google Scholar
• Khellaf M, Chabrol A, Mahevas M. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014; 89(2):194-198. https://doi.org/10.1002/ajh.23609 PubMed Google Scholar
• Aggarwal M, Mahapatra M, Seth T, Tyagi S, Tandon N, Saxena R. Thyroid dysfunction in patients with immune thrombocytopenia: prevalence and it's impact on outcome. Indian J Hematol Blood Transfus. 2022; 38(1):173-177. https://doi.org/10.1007/s12288-021-01460-7 PubMed PubMed Central Google Scholar
• Velayutham K, Selvan SS, Unnikrishnan AG. Prevalence of thyroid dysfunction among young females in a South Indian population. Indian J Endocrinol Metab. 2015; 19(6):781-784. https://doi.org/10.4103/2230-8210.167546 PubMed PubMed Central Google Scholar
• Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013; 17(4):647-652. https://doi.org/10.4103/2230-8210.113755 PubMed PubMed Central Google Scholar
• Cordiano I, Betterle C, Spadaccino CA, Soini B, Girolami A, Fabris F. Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes?. Clin Exp Immunol. 1998; 113(3):373-378. https://doi.org/10.1046/j.1365-2249.1998.00677.x PubMed PubMed Central Google Scholar
• McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008; 83(2):150-154. https://doi.org/10.1002/ajh.20992 PubMed Google Scholar
• Mahevas M, Moulis G, Andres E. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020; 190(4):e224-e229. https://doi.org/10.1111/bjh.17024 PubMed PubMed Central Google Scholar
• DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009; 146(1):104-112. https://doi.org/10.1111/j.1365-2141.2009.07714.x PubMed Google Scholar
• Shragai T, Lebel E, Deshet D. Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. Br J Haematol. 2020; 191(5):863-867. https://doi.org/10.1111/bjh.17017 PubMed Google Scholar
• Stasi R, Sarpatwari A, Segal JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009; 113(6):1231-1240. https://doi.org/10.1182/blood-2008-07-167155 PubMed Google Scholar
• Zhang H, Chien M, Hou Y. Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3, and MPL mutations. Blood Adv. 2022. https://doi.org/10.1182/bloodadvances.2021006701 PubMed Google Scholar
• Pecci A, Balduini CL. Inherited thrombocytopenias: an updated guide for clinicians. Blood Rev. 2021; 48:100784. https://doi.org/10.1016/j.blre.2020.100784 PubMed Google Scholar
• Balduini C, Freson K, Greinacher A. The EHA research roadmap: platelet disorders. Hemasphere. 2021; 5(7):e601. https://doi.org/10.1097/HS9.0000000000000601 PubMed PubMed Central Google Scholar
• Balduini CL, Melazzini F, Pecci A. Inherited thrombocytopenias-recent advances in clinical and molecular aspects. Platelets. 2017; 28(1):3-13. https://doi.org/10.3109/09537104.2016.1171835 PubMed Google Scholar
• Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016; 91(9):907-911. https://doi.org/10.1002/ajh.24434 PubMed Google Scholar
• Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. Haematologica. 2019; 104(6):1124-1135. https://doi.org/10.3324/haematol.2019.218883 PubMed PubMed Central Google Scholar
• Nazi I, Kelton JG, Larche M. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013; 122(11):1946-1953. https://doi.org/10.1182/blood-2013-04-494096 PubMed PubMed Central Google Scholar
• Lee EJ, Beltrami-Moreira M, Al-Samkari H. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022; 139(10):1564-1574. https://doi.org/10.1182/blood.2021013411 PubMed PubMed Central Google Scholar
• Bradbury CA, Pell J, Hill Q. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021; 385(10):885-895. https://doi.org/10.1056/NEJMoa2100596 PubMed Google Scholar
• Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007; 110(10):3526-3531. https://doi.org/10.1182/blood-2007-01-065763 PubMed Google Scholar
• Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995; 85(2):351-358. https://doi.org/10.1182/blood.V85.2.351.bloodjournal852351 PubMed Google Scholar
• Bussel JB, Kuter DJ, George JN. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006; 355(16):1672-1681. https://doi.org/10.1056/NEJMoa054626 PubMed Google Scholar
• Bussel JB, Cheng G, Saleh MN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357(22):2237-2247. https://doi.org/10.1056/NEJMoa073275 PubMed Google Scholar
• Bussel JB, Kuter DJ, Aledort LM. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014; 123(25):3887-3894. https://doi.org/10.1182/blood-2013-07-514398 PubMed Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019; 104(6):1112-1123. https://doi.org/10.3324/haematol.2018.212845 PubMed PubMed Central Google Scholar
• Bussel J, Kulasekararaj A, Cooper N. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019; 56(4):262-278. https://doi.org/10.1053/j.seminhematol.2019.09.001 PubMed Google Scholar
• Liu ZJ, Deschmann E, Ramsey HE. Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro. Blood Adv. 2022; 6(1):13-27. https://doi.org/10.1182/bloodadvances.2021004207 PubMed PubMed Central Google Scholar
• Cantoni S, Carpenedo M, Mazzucconi MG. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018; 93(1):58-64. https://doi.org/10.1002/ajh.24935 PubMed Google Scholar
• Lakhwani S, Perera M, Fernandez-Fuertes F. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017; 99(4):372-377. https://doi.org/10.1111/ejh.12932 PubMed Google Scholar
• Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol. 2021; 96(10):E373-E376. https://doi.org/10.1002/ajh.26277 PubMed Google Scholar
• Piatek CI, Jamieson B, Vredenburg M. Characterization of thromboembolic events occurring during the avatrombopag immune thrombocytopenia (ITP) clinical development program. Blood. 2020; 136(Suppl 1):39. https://doi.org/10.1182/blood-2020-141273 PubMed Google Scholar
• Pavord S, Thachil J, Hunt BJ. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020; 189(6):1038-1043. https://doi.org/10.1111/bjh.16775 PubMed PubMed Central Google Scholar
• American Hematology Scoiety. COVID-19 and ITP. 2022. Publisher Full Text Google Scholar
• Bussel J, Arnold DM, Grossbard E. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93(7):921-930. https://doi.org/10.1002/ajh.25125 PubMed PubMed Central Google Scholar
• Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019; 133(19):2027-2030. https://doi.org/10.1182/blood-2018-11-852491 PubMed Google Scholar
• Strich JR, Tian X, Samour M. Fostamatinib for the treatment of hospitalized adults with COVD-19 A [sic] randomized trial. Clin Infect Dis. 2021. Google Scholar
• Mageau A, Terriou L, Ebbo M. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022; 97(1):10-17. https://doi.org/10.1002/ajh.26378 PubMed Google Scholar
• Theilacker C, Ludewig K, Serr A. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis. 2016; 62(7):871-878. https://doi.org/10.1093/cid/civ1195 PubMed Google Scholar
• Tahir F, Ahmed J, Malik F. Post-splenectomy sepsis: a review of the literature. Cureus. 2020; 12(2):e6898. https://doi.org/10.7759/cureus.6898 PubMed PubMed Central Google Scholar
• Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ. 2005; 331(7514):417-418. https://doi.org/10.1136/bmj.331.7514.417 PubMed PubMed Central Google Scholar
• Feng Q, Tamimi R, Mu Y, Pen J, Bussel JB. Splenectomy results in venous thromboembolic events in women: a Nurses Health Study. Blood. 2021; 138(Suppl 1):3163. https://doi.org/10.1182/blood-2021-152672 PubMed Google Scholar
• Rodeghiero F, Marranconi E. Management of immune thrombocytopenia in women: current standards and special considerations. Expert Rev Hematol. 2020; 13(2):175-185. https://doi.org/10.1080/17474086.2020.1711729 PubMed Google Scholar
• Upson K, Harmon QE, Heffron R. Depot medroxyprogesterone acetate use and blood lead levels in a cohort of young women. Environ Health Perspect. 2020; 128(11):117004. https://doi.org/10.1289/EHP7017 PubMed PubMed Central Google Scholar
• Bussel JB, Druzin ML, Cines DB, Samuels P. Thrombocytopenia in pregnancy. Lancet. 1991; 337(8735):251. https://doi.org/10.1016/0140-6736(91)92228-T PubMed Google Scholar
• Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993; 329(20):1463-1466. https://doi.org/10.1056/NEJM199311113292005 PubMed Google Scholar
• Boehlen F, Hohlfeld P, Extermann P, Perneger TV, de Moerloose P. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000; 95(1):29-33. https://doi.org/10.1097/00006250-200001000-00006 Google Scholar
• Sainio S, Kekomaki R, Riikonen S, Teramo K. Maternal thrombocytopenia at term: a population-based study. Acta Obstet Gynecol Scand. 2000; 79(9):744-749. https://doi.org/10.1034/j.1600-0412.2000.079009744.x PubMed Google Scholar
• Khanuja K, Levy AT, McLaren RA Jr, Berghella V. Pre- and postpregnancy platelet counts: evaluating accuracy of gestational thrombocytopenia and immune thrombocytopenia purpura diagnoses. Am J Obstet Gynecol MFM. 2022; 4(3):100606. https://doi.org/10.1016/j.ajogmf.2022.100606 PubMed Google Scholar
• Dockree S, Shine B, Impey L, Mackillop L, Randeva H, Vatish M. Improving diagnostic accuracy in pregnancy with individualised, gestational age-specific reference intervals. Clin Chim Acta. 2022; 527:56-60. https://doi.org/10.1016/j.cca.2022.01.007 PubMed Google Scholar
• Chen Q, Liu F, Sun X, Wang C. High level of estradiol induces megakaryocyte apoptosis and impairs proplatelete formation via MST1-FOXO1 axis during pregnancy in patients with immune thrombocytopenia. European Hematology Association; 2021 06/09/2021. EHA Library; (no. 324706). Publisher Full Text Google Scholar
• Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011; 12(4):503-516. https://doi.org/10.1517/14656566.2011.545818 PubMed Google Scholar
• Mantero F, Opocher G, Armanini D, Filipponi S. 11 Beta-hydroxylase deficiency. J Endocrinol Invest. 1995; 18(7):545-549. https://doi.org/10.1007/BF03349766 PubMed Google Scholar
• Sun D, Shehata N, Ye XY. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016; 128(10):1329-1335. https://doi.org/10.1182/blood-2016-04-710285 PubMed Google Scholar
• Lakkaraja M, Berkowitz RL, Vinograd CA. Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2016; 215(4):471. https://doi.org/10.1016/j.ajog.2016.04.033 PubMed Google Scholar
• Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011; 117(5):1499-1506. https://doi.org/10.1182/blood-2010-07-295444 PubMed Google Scholar
• Michel M, Novoa MV, Bussel JB. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol. 2003; 123(1):142-146. https://doi.org/10.1046/j.1365-2141.2003.04567.x PubMed Google Scholar
• Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011; 57(12):1401-1402. Google Scholar
• Sukenik-Halevy R, Ellis MH, Fejgin MD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008; 63(3):182-188. https://doi.org/10.1097/OGX.0b013e318164013c PubMed Google Scholar
• Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001; 71(8):1051-1055. https://doi.org/10.1097/00007890-200104270-00006 PubMed Google Scholar
• Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008; 7(3):219-222. https://doi.org/10.1517/14740338.7.3.219 PubMed Google Scholar
• Kong Z, Qin P, Xiao S. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017; 130(9):1097-1103. https://doi.org/10.1182/blood-2017-01-761262 PubMed Google Scholar
• Michel M, Ruggeri M, Gonzalez-Lopez TJ. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020; 136(26):3056-3061. https://doi.org/10.1182/blood.2020007594 PubMed Google Scholar
• Bussel JB, Cooper N, Lawrence T. Surveillance program of romiplostim use connected to pregnancy. Blood. 2021; 138(Suppl 1):585. https://doi.org/10.1182/blood-2021-150314 PubMed Google Scholar
• Zhang H, Zhang BM, Guo X. Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Haematologica. 2020; 105(3):e129-e132. https://doi.org/10.3324/haematol.2019.226688 PubMed PubMed Central Google Scholar
• Ogawa S. Genetics of MDS. Blood. 2019; 133(10):1049-1059. https://doi.org/10.1182/blood-2018-10-844621 PubMed PubMed Central Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000; 160(11):1630-1638. https://doi.org/10.1001/archinte.160.11.1630 PubMed Google Scholar
• Tsuda H, Tsuji T, Tsuji M, Yamasaki H. Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients. Ann Hematol. 2017; 96(11):1915-1920. https://doi.org/10.1007/s00277-017-3095-6 PubMed Google Scholar
• Sokal A, de Nadai T, Maquet J. Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry. Br J Haematol. 2022; 196(5):1262-1270. https://doi.org/10.1111/bjh.17935 PubMed Google Scholar
• Hasan A, Michel M, Patel V. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009; 84(10):661-665. https://doi.org/10.1002/ajh.21512 PubMed PubMed Central Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004; 104(9):2623-2634. https://doi.org/10.1182/blood-2004-03-1168 PubMed Google Scholar
• Mahevas M, Guillet S, Viallard J-F. Rate of prolonged response after stopping thrombopoietin-receptor agonists treatment in primary immune thrombocytopenia (ITP): results from a nationwide prospective multicenter interventional study (STOPAGO). Blood. 2021; 138(Suppl 1):583. https://doi.org/10.1182/blood-2021-152767 PubMed Google Scholar
• Vianelli N, Auteri G, Buccisano F. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. 2022; 101(5):963-978. https://doi.org/10.1007/s00277-022-04786-y PubMed PubMed Central Google Scholar
• Newland AC, Sanchez-Gonzalez B, Rejto L. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020; 95(2):178-187. https://doi.org/10.1002/ajh.25680 PubMed PubMed Central Google Scholar
• Robak T, Kazmierczak M, Jarque I. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020; 4(17):4136-4146. https://doi.org/10.1182/bloodadvances.2020002003 PubMed PubMed Central Google Scholar
• Kuter DJ, Efraim M, Mayer J. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022; 386(15):1421-1431. https://doi.org/10.1056/NEJMoa2110297 PubMed Google Scholar
• Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep. 2021; 23(9):74. https://doi.org/10.1007/s11926-021-01037-3 PubMed PubMed Central Google Scholar
• Rodeghiero F, Cantoni S, Carli G, et a. Practical recommendations for the management of patients with ITP during the COVID-19 pandemic. Mediterr J Hematol Infect Dis. 2021; 13(1):e2021032. https://doi.org/10.4084/MJHID.2021.032 PubMed PubMed Central Google Scholar
• Lee EJ, Liu X, Hou M, Bussel JB. Immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2021; 193(6):1093-1095. https://doi.org/10.1111/bjh.17457 PubMed PubMed Central Google Scholar
• Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005; 10(2):149-159. https://doi.org/10.1016/j.siny.2004.09.016 PubMed Google Scholar
• Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008; 103(5):1203-1209. https://doi.org/10.1111/j.1572-0241.2007.01756.x PubMed Google Scholar
• Anglin BV, Rutherford C, Ramus R, Lieser M, Jones DB. Immune thrombocytopenic purpura during pregnancy: laparoscopic treatment. JSLS. 2001; 5(1):63-67. Google Scholar

Article Information

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .

Article Usage

Statistics from altmetric.com, how to cite.

• Haematologica

Download Citation

• Endnote/Zotero/Mendeley (RIS)

Share Article

Request permissions.

To create an adaptation, translation, or derivative of the original work, for commercial e-prints and printed articles further permission is required. For information contact: [email protected]

Other types of copyright management , can be agreed with the Editorial office.

• Current issue
• About Haematologica
• Editorial Team
• Our policies

For Authors

• Author Guidelines
• Submit Manuscript
• Track Manuscript

For Reviewers

• Reviewer Guidelines
• Access Your Profile
• Access Your Tasks

For Advertisers

• Informations For Advertising
• Review Articles
• Guidelines Articles
• Cookie Policy
• Newsletter Privacy Policy
• Privacy Policy
• Rights & Permissions
• Development

Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study

Affiliations.

• 1 Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.
• 2 Service de Médecine Interne, Centre Hospitalier Alpes Léman, Contamine sur Arve, France.
• 3 Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
• 4 Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France.
• 5 Service de Médecine Interne et d'Immunopathologie-IUCT-Oncopole, CHU de Toulouse, Toulouse, France.
• 6 Service de Médecine Interne, CHU de Poitiers, Poitiers, France.
• 7 Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin, AP-HP, Université de Paris, Paris, France.
• 8 Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Université de Paris, Centre of Research in Epidemiology and Statistics, Paris, France.
• 9 Service d'Hématologie, CHU Brest, Université de Brest, Brest, France.
• 10 Service de Médecine Interne, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France.
• 11 Institut d'Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France.
• 12 Service de Médecine Interne, Hôpital Haut-L'évêque, Université de Bordeaux, France.
• 13 Service de Médecine Interne, Hôpital Jean Verdier, AP-HP, Bondy, France.
• 14 Service de Médecine Interne, Hôpital Charles Nicolle, Université de Rouen, Rouen, France.
• 15 Service d'Onco-hématologie Adulte, Hôpital Saint-Vincent de Paul, GH de l'institut Catholique de Lille, Lille, France.
• 16 Service d'Immuno-hématologie, Hôpital Saint Louis, Paris, France.
• 17 Service d'Hématologie clinique, CHU d'Amiens, Amiens, France.
• 18 Service de Médecine Interne, CHU de Nantes, Nantes, France.
• 19 Service de Médecine Interne et d'Immunologie Clinique, CHU Lille, Université de Lille, Lille, France.
• 20 Service d'Immunologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France.
• 21 Service de Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, Université Paris Sacly, Le Kremlin-Bicêtre, France.
• 22 Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France.
• 23 Service de Médecine Interne, CH Simone Veil, Blois, France.
• 24 Service de Médecine Interne et d'Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, CHU Dijon-Bourgogne, Dijon, France.
• 25 Service de Médecine Interne, Hôpital Bichat, AP-HP, Paris, France et Université de Paris, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Paris, France.
• 26 Service de Médecine Interne et Médecine Vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, Université de Lyon, Lyon, France.
• 27 Laboratoire de Biométrie et Biologie Évolutive, CNRS-UMR 5588, Université Lyon 1, Lyon, France.
• 28 Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France.
• 29 Service d'Obstétrique et Gynécologie, Hôpital Antoine-Béclère, AP-HP, Université Paris-Saclay, Clamart, France.
• 30 Service d'Hématologie, Hôpital d'Anger, INSERM, CRCINA, Université d'Angers, Angers, France.
• 31 Service d'Hématologie Clinique, CH Sud Francilien, Corbeil Essonnes, France.
• 32 Service de Médecine Interne, CHU de Besançon, Besançon, France.
• 33 Service de Médecine Interne, CH Général Delafontaine, St Denis, France.
• 34 Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France.
• 35 Service de Médecine Interne, Hôpital Beaujon, AP-HP, Clichy, France.
• 36 Service de Médecine Interne, Hôpital de la Conception, AP-HP, Université Aix-Marseille, Marseille, France.
• 37 Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.
• 38 Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
• 39 Centre Hospitalier Inter-Communal de Créteil, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Equipe Immunorégulation et Biothérapie (I-BIOT), Université Paris Est Créteil, Univ Paris Est Créteil, INSERM U955, Institut Mondor De Recherche Biomédicale (IMRB), Créteil, France.
• PMID: 36054922
• PMCID: PMC10644036
• DOI: 10.1182/blood.2022017277

The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Publication types

• Observational Study
• Multicenter Study
• Research Support, Non-U.S. Gov't
• Cohort Studies
• Infant, Newborn
• Pregnancy Complications, Hematologic* / epidemiology
• Pregnancy Complications, Hematologic* / therapy
• Prospective Studies
• Purpura, Thrombocytopenic, Idiopathic* / complications
• Purpura, Thrombocytopenic, Idiopathic* / epidemiology
• Purpura, Thrombocytopenic, Idiopathic* / therapy
• Retrospective Studies
• Thrombocytopenia, Neonatal Alloimmune* / therapy
• 7-(4'-(2-nitroimidazole-1-yl)butyl)theophylline

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• v.57(1); 2022 Mar 31

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young hoon park.

1 Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea

Dae-Young Kim

2 Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji Univerisity, Seoul, Korea

Seongkoo Kim

3 Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Young Bae Choi

4 Department of Pediatrics, Ajou University School of Medicine, Ajou Univeristy Hospital, Suwon, Korea

Dong-Yeop Shin

5 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

Jin Seok Kim

6 Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea

Won Sik Lee

7 Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea

Yeung-Chul Mun

Jun ho jang.

8 Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Jong Wook Lee

9 Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

10 Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea

Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.

INTRODUCTION

Purpose of these guidelines.

These guidelines aimed to provide helpful recommendations for managing adult and pediatric patients with immune thrombocytopenic purpura (ITP). In addition, these guidelines aim to provide clinical support for the decision-making process regarding different treatment courses.

Clinical situation and impact of ITP

ITP is an acquired autoimmune disorder characterized by low platelet count resulting from platelet destruction and impaired production. The incidence of ITP in Western countries is 2–5 per 100,000 person-years [ 1 - 5 ]. In national studies using the Korea Health Insurance Research and Assessment (HIRA) database, the incidence rate of ITP for all ages is 5.3 per 100,000 person-years, while it is 13.39 and 18.1 per 100,000 person-years for children aged <18 years [ 6 - 8 ]. ITP can be an isolated primary event or secondary to other clinical conditions. ITP is a heterogeneous disorder with variable clinical symptoms and signs and remains a diagnosis of exclusion of other causes of thrombocytopenia [ 9 ]. The clinical course of ITP may also vary depending on whether it is primary ITP (not associated with other conditions), occurring in the setting of autoimmune cytopenia (Evans syndrome), a manifestation of primary immunodeficiency, or is associated with autoimmune or infectious causes (secondary ITP). In secondary ITP, treatment is often directed towards managing underlying causes.

Bleeding episodes are often unpredictable, and patients with ITP, even in severe thrombocytopenia, may not have bleeding, except bruising and petechiae [ 10 - 12 ]. However, severe bleeding may occur [ 11 - 13 ]. Serious bleeding was reported in 9.5% [95% confidence interval (CI), 4.1–17.1] of adults [ 11 ]. Adults with ITP have a 1.3–2.2-fold higher mortality rate than the general population due to cardiovascular events, infectious diseases, and bleeding episodes [ 14 ]. In addition, ITP has a significant impact on health-related quality of life (HRQoL) [ 15 , 16 ].

Whether a patient can be observed without treatment or requires further treatment is complex and varies based on comorbidities, medications, and age, all of which affect the risk of bleeding [ 17 , 18 ]. In addition, management approaches may vary according to the duration of the disease, accessibility to care, quality of life implications, and preferences of the patient and clinicians. Considering the inter-patient variability in the pathophysiology of immune dysregulation and the lack of effective predictors of treatment response, the choice of appropriate therapy may vary significantly among physicians when the treatment has been decided [ 19 ].

For the 2022 update, an expert panel reviewed the evidence published since the 2017 Korean recommendation [ 20 ]. In these guidelines, the expert panel recommended valuable principles for managing adult and pediatric patients with ITP based on evidence and expert opinions.

RECOMMENDATIONS

Management of adult patients with newly diagnosed itp, corticosteroids versus observation, recommendation 1.

In adult patients with newly diagnosed ITP and a platelet count <20×10 9 /L without symptoms or with minor mucocutaneous bleeding, we recommend corticosteroids rather than observation.

To choose corticosteroid versus observation, physicians should consider the level of platelet count, additional comorbidities, use of anticoagulant or antiplatelet agents, need for subsequent procedures, and patient age.

The benefits cannot be estimated from the data because of the lack of direct comparison results [ 21 - 27 ]. The response rate of the platelet count at 7 days was 55.8% with corticosteroids; however, the overall remission rate was relatively low (30.2%) [ 21 ]. The harms and burdens could not be precisely estimated from the data because of the lack of direct comparison results. Undesirable adverse effects of observation exist in this setting, considering that thrombocytopenia is a surrogate for future bleeding events and treatment failure in adult patients. Bleeding episodes (3.3%) and mortality (5.7%) were only reported in the corticosteroid-treated group [ 26 ].

Recommendation 2

In adult patients with newly diagnosed ITP and a platelet count ≥20×10 9 /L without symptoms or minor mucocutaneous bleeding, we recommend observation rather than corticosteroids. For patients with a platelet count at the lower end of this threshold, those with additional comorbidities, anticoagulant or antiplatelet agents, or need to follow the procedures. Corticosteroid treatment may be appropriate for elderly patients (aged >60 yr).

The benefit cannot be precisely estimated from the data because of the lack of direct comparison results. However, major bleeding episodes were not different and low in both arms (corticosteroids vs. observation: 0.9% vs. 0%) [ 28 - 32 ]. Based on indirect evidence, the side effects of corticosteroids are not trivial; therefore, the undesirable adverse effects of corticosteroids are moderate.

Duration and type of corticosteroids

Recommendation 3.

In adult patients with newly diagnosed ITP, we recommend a short course (≤6 wk) of prednisone rather than a prolonged course (>6 wk, including treatment and tapering).

No studies supporting short courses of prednisone are currently available, and this recommendation is based on expert experience [ 33 - 35 ]. It is presumed that a trivial benefit exists in continuing corticosteroids for more than 6 weeks, and many patients require additional treatment. For patients requiring further treatment, an alternative therapy is preferable to continued corticosteroid exposure. The likelihood of harm and risk of adverse events was enormous with the continuation of corticosteroids for more than 6 weeks. Adverse events included hypertension, hyperglycemia, sleep and mood disturbances, epigastric soreness, ulcer formation, glaucoma, myopathy, and osteoporosis.

Recommendation 4

In adult patients with newly diagnosed ITP, we recommend either prednisone (0.5–2.0 mg/kg/day) or dexamethasone (40 mg/day for 4 days) as the type of initial corticosteroid treatment. If we stress the rapidity of the platelet count response, dexamethasone may be preferable to prednisone, considering that the response at 7 days was more desirable with dexamethasone.

Randomized study data showed an increased platelet count response at 7 days to dexamethasone [relative risk (RR), 1.31; 95% CI, 1.11–1.54] [ 21 - 23 ]. The remission rate was higher among the dexamethasone-treated patients than with prednisone (RR, 2.96; 95% CI, 1.03–8.45); however, the confidence level was low because the definition of remission applied by the trials was indirect, and the dose of corticosteroid was heterogeneous [ 21 - 23 , 25 , 28 , 36 , 37 ]. No clear benefit was found regarding the 1 month response rate, durable response rate, or incidence of major bleeding episodes. The duration of the initial response following a cycle of dexamethasone varied. We also recommend that the platelet count should be monitored frequently.

Despite the lack of direct evidence, the risk of adverse events in clinical practice varies according to the dose and duration of corticosteroid treatment, comorbidities, and patient age. Concerns regarding dexamethasone in patients with underlying diabetes and the elderly (aged >60 yr) also exist.

Recommendation 5

In adult patients with newly diagnosed ITP, we recommend corticosteroids alone rather than corticosteroids combined with rituximab as the initial treatment. An initial course of corticosteroids combined with rituximab may be preferable when the possibility of remission is higher than the concerns regarding the potential side effects of rituximab.

Moderate effects were observed with concomitant corticosteroids and rituximab, particularly a higher durable response rate (RR, 1.70; 95% CI, 1.34–2.16) and remission rate (RR, 1.58; 95% CI, 1.00–2.52) [ 38 - 40 ]. No difference was observed regarding the impact on the response rate at 1 month, prevention of major bleeding episodes or mortality, and no data on HRQoL. The certainty level in the evidence for benefits was extremely low due to the absence of HRQoL data, unknown and non-standardized corticosteroid doses for comparison, and the absence of long-term follow-up results. The prioritized outcome of infection was not different between the two treatments, even though the CI was significant (RR, 3.18; 95% CI, 0.13–76.25).

Management of adult patients with corticosteroid-dependent or refractory ITP

Eltrombopag versus romiplostim, recommendation 6.

In adult patients with corticosteroid-dependent or refractory ITP for more than 3 months, we recommend a thrombopoietin receptor agonist (TPO-RA), either eltrombopag or romiplostim. Physicians should consider the preferences of individual patients when choosing daily oral medications or weekly subcutaneous injections.

A comparison was made between the durable response rates of eltrombopag and romiplostim (odds ratio=0.20; 95% CI, 0.01–2.13) [ 41 - 43 ]. The major bleeding rates and discontinuation or reduction rates of corticosteroids could not be estimated from the data because of a lack of comparisons. However, the desirable effects were minimally different. There were no significant differences in the outcomes, including durable response, bleeding, and corticosteroid discontinuation or reduction rates. The undesirable effects are trivial. Elevation of alanine/aspartate transaminase related to eltrombopag was mild and reversible in most participants; therefore, it did not affect the balance of undesirable events. No net health benefits or harmful differences related to eltrombopag or romiplostim were observed. Based on the available evidence, it is presumed that there is no difference between the two treatments. Preference of the patients for the route of administration – oral daily medication compared with weekly subcutaneous injection– likely affects treatment decision-making.

Second-line therapies: TPO-RA and splenectomy

Recommendation 7.

In adult patients with ITP lasting ≥3 months who are corticosteroid-dependent or unresponsive to corticosteroids, we recommend TPO-RA rather than splenectomy. Splenectomy should be postponed for at least 12 months after diagnosis because of the possibility of spontaneous remission in the first year. For patients with ITP lasting >12 months, a splenectomy can only be performed in those with limited indications.

The American Society of Hematology (ASH) guidelines suggest either splenectomy or TPO-RA for corticosteroid-dependent patients or do not respond to corticosteroids [ 44 ]. Despite the lack of direct evidence, both treatment options are associated with a more durable response. No difference in major bleeding was observed between the patients treated with splenectomy and those treated with TPO-RAs (4.6% and 3.5%, respectively). As there is no single treatment optimal for all patients with ITP, treatment should be individualized based on the duration of ITP, age of the patient, medical condition, and patient preferences [ 44 ].

For patients with ITP of 3–12 months, because of the possibility of spontaneous remission in the first year, it is recommended to postpone splenectomy to 12 months from diagnosis [ 45 - 50 ]. For such patients, TPO-RA is the primary treatment option because of its greater response durability. Splenectomy and TPO-RA can be viable options for patients with ITP lasting >12 months [ 51 - 66 ]. A splenectomy is an option for patients who prioritize durable responses and avoid long-term treatment. Currently, the use of splenectomy as a second-line treatment for ITP is gradually decreasing. In a Korean ITP study, only 3% of treated patients received splenectomy as a second-line treatment [ 6 ]. This low incidence of splenectomy for ITP results from high post-splenectomy morbidity and mortality related to the operation and long-term complications, such as infection, cardiovascular events, and venous thromboembolism, especially in older patients [ 6 ]. Alternative effective treatment options, such as TPO-RA, are also available for adult nonsplenectomized patients who have a medically unfit condition to splenectomy, as suggested by the Korean ITP guidelines in 2017. Unlike the ASH guidelines, the International Consensus Report (ICR) guidelines recommend splenectomy only after medical treatment failure [ 67 ]. Based on the current data, splenectomy should be performed under limited indications considering the age, comorbidities that can worsen the risk of surgery, and patient preference [activity levels, occupation, need for procedures, acceptance of minor bleeding, the persistence of treatment duration (chronic therapy vs. limited therapy), preference for daily tablets or weekly injections, and financial ability]. Young patients with an active lifestyle, including those who participate in high-risk activities, may prefer splenectomies. In addition, other patients who do not comply with the medication (dietary restriction for eltrombopag and weekly injection of romiplostim) may consider splenectomy. For patients who prefer medical treatment and prioritize avoiding surgery, a suitable option is the TPO-RA. The common adverse effects of TPO-RA are gastrointestinal symptoms, mild transaminase elevation, and headache, most of which are mild. Bone marrow fibrosis is a potential side effect of concern with the use of TPO-RAs; however, the risk of clinically meaningful fibrosis seems to be low. Thrombotic events of TPO-RAs should be considered in patients with ITP with significant risk factors for venous and arterial thrombosis. In addition, the disadvantage of a relatively high cost due to the long-term use of a TPO-RA should be considered when discussing treatment options. Most importantly, for patients who prioritize achieving a durable response, the best option is TPO-RA. An individualized approach for selecting second-line treatment based on ITP duration and patient preference is shown in Fig. 1 .

Algorithm for the selection of second-line therapy in adult patients with ITP.

Management of pediatric patients with newly diagnosed ITP

Treatment vs. observation, recommendation 8.

In pediatric patients with newly diagnosed ITP without bleeding or with minor bleeding, observation rather than corticosteroids is recommended.

There was no perceived benefit of corticosteroids in terms of durable platelet response (78.5% with corticosteroids and 87.3% with observation), remission (76.6% with corticosteroids and 63.6% with observation), or reduction in major bleeding (0% for both treatments) in this setting [ 68 - 69 ]. In addition, the undesirable effects of corticosteroids increase in proportion to the treatment duration.

Recommendation 9

In pediatric patients with newly diagnosed ITP without bleeding or with minor bleeding, we recommend observation rather than intravenous immunoglobulin (IVIG) or anti-D immunoglobulin.

A randomized trial of IVIG over observation showed no differences in outcomes at 12 months and durable response. The incidence of bleeding and mortality was similar between the two groups (0.6% and 1.8% with IVIG and 0% and 0% with observation for bleeding and mortality, respectively) [ 69 - 73 ]. Although there was a lack of direct comparisons, there was only a small benefit from anti-D immunoglobulin. No data are available on major bleeding and mortality associated with anti-D immunoglobulins. IVIG has side effects, such as infusion-related symptoms, thrombosis, and acute renal failure, and anti-D immunoglobulins such as intravascular hemolysis [ 69 - 73 ].

Type and duration of corticosteroids

Recommendation 10.

We recommend 7 days or shorter courses of corticosteroids rather than longer than 7 days in pediatric patients with newly diagnosed ITP with non-life-threatening mucosal bleeding and diminished HRQoL. In addition, we recommend 2–4 mg/kg/day of prednisolone (maximum 120 mg/day) for 5–7 days, rather than 0.6 mg/kg/day of dexamethasone (maximum 40 mg/day) for 4 days.

Given the low rate of bleeding, high rate of spontaneous remission, overall low morbidity in the pediatric population, and lack of evidence for the benefit of long-term corticosteroids, there was likely a small benefit in continuing corticosteroids for longer than 7 days [ 44 ]. A longer course of corticosteroids (>7 days) is likely to increase the risk of adverse events, resulting in poor treatment adherence in this population. In the absence of increased benefits with a longer course of corticosteroids and the side effects associated with prolonged corticosteroid exposure, we recommend that the balance of effects favored 7 days or shorter course of corticosteroids over longer periods [ 44 ]. There are limited data on treatment with dexamethasone compared with prednisolone in the pediatric population. Higher corticosteroid doses of dexamethasone used in adult trials are deemed potentially intolerable by some pediatric patients with regard to short-term side effects. In the absence of data, there is no strong evidence suggesting that dexamethasone is superior to prednisolone.

Treatment of pediatric patients with non-life-threatening bleeding and diminished HRQoL

Recommendation 11.

In pediatric patients with newly diagnosed ITP with non-life-threatening bleeding and diminished HRQoL, we recommend corticosteroids rather than anti-D immunoglobulins or IVIG.

Based on randomized trial data, only trivial benefits were observed with IVIG compared with corticosteroids regarding durable response, remission rate, prevention of bleeding events, and mortality [ 44 , 70 - 73 ]. In addition, a short course of corticosteroids is usually associated with mild side effects in most pediatric patients. However, some concerns related to anti-D immunoglobulins and IVIG, leading to the need for additional medical interventions.

Management of pediatric patients with ITP who are unresponsive to first-line treatment

Recommendation 12.

In pediatric patients with ITP with non-life-threatening mucosal bleeding and diminished HRQoL who do not respond to first-line treatment, we recommend using TPO-RAs rather than rituximab or splenectomy.

Although there are no data available for direct comparison of TPO-RAs with either rituximab or splenectomy, TPO-RAs show a moderate benefit over rituximab and splenectomy in various studies of pediatric patients with ITP who are unresponsive to first-line treatment [ 44 , 74 - 76 ]. Compared with rituximab and splenectomy, TPO-RAs provide a stable long-term platelet response and reduce bleeding events [ 74 - 76 ]. However, there is concern about developing persistent hypogammaglobulinemia after rituximab treatment in the pediatric population [ 44 , 74 - 76 ]. In addition, operative complications associated with splenectomy were identified in 5.9% of children [ 44 ]. However, thrombosis was not observed in any children [ 44 ].

Maintenance for responders to a TPO-RA

Recommendation 13.

In adult patients with ITP who respond to TPO-RAs, we recommend using the lowest dose of TPO-RAs, sufficient to maintain a platelet count ≥50×10 9 /L.

TPO-RAs are generally used as a maintenance treatment for ITP. However, the optimal dose of TPO-RAs and the platelet count target necessary to maintain response and reduce bleeding in responders to TPO-RAs differ slightly depending on the study [ 77 , 78 ]. In published studies on romiplostim, most adult patients who responded to romiplostim achieved and maintained a platelet count ≥50×10 9 /L with a median dose of 2 mcg/kg (up to 10 mcg/kg) [ 78 ]. In prescribed information of two TPO-RAs, the lowest dose of TPO-RAs was recommended to achieve and maintain a platelet count ≥50×10 9 /L as necessary to reduce the risk for bleeding. In a single-arm phase II study of romiplostim in adults with primary ITP who had received first-line therapy (remission study), 75 patients who achieved a response started tapering and discontinuation of romiplostim [ 79 ]. Patients with a platelet count ≥50×10 9 /L at 12 months started to receive a dose taper, in which the romiplostim dose was decreased, and the platelet count was maintained. In this study, 32% (24/75) of patients who discontinued romiplostim maintained platelet count ≥50×10 9 /L without any additional treatment for 24 consecutive weeks.

Other treatments for adult patients with ITP

Rituximab is a monoclonal antibody against the CD20 antigen that targets the B cell-producing antibodies for platelets. Rituximab is usually administered at 375 mg/m 2 intravenously every 4 weeks. In adults with ITP who fail to respond to TPO-RA or experience relapse after discontinuing TPO-RA, rituximab can be administered as a third-line therapy [ 80 ].

Azathioprine is administered at an oral dose of 50–200 mg/day in adult patients and is sometimes administered with danazol; however, there is little data to support an improved response to the combination. It takes several months to have a full effect on ITP. Azathioprine is one of the drugs deemed “safe” for patients with ITP in pregnancy, without increased risk of fetal malformation, and safe during lactation. Major adverse events included nausea, infection, liver function abnormalities, neutropenia, and anemia [ 81 ].

Cyclophosphamide is a chemotherapeutic agent that has been used since 1959 to treat malignant disease at high doses and as an immunosuppressive agent to treat autoimmune disorders at low doses. Cyclophosphamide is usually delivered as an oral dose of 50–200 mg/day for adult patients. Major adverse events include bone marrow suppression, infection, infertility, secondary malignancies, and hemorrhagic cystitis. However, its use is contraindicated during pregnancy and lactation [ 82 ].

Cyclosporine A levels were adjusted by monitoring drug levels. However, the usual starting dose is 3–6 mg/kg/day, with a maximum dose of 200 mg for adult patients. Major adverse events were gingival hyperplasia, hypertension, renal toxicity, and emesis. Therefore, its use is contraindicated during pregnancy and lactation [ 83 ].

Danazol is usually administered at an oral dose of 200–800 mg/day in adults. Its androgenic effects are related to major adverse events (especially in women), transaminitis, weight gain, acne, rash, mood changes, amenorrhea, and virilization. Therefore, clinicians should perform liver function tests at least once a month. However, they are contraindicated during pregnancy and lactation. It has sometimes been used in combination with azathioprine, but there is little evidence to support the added benefits of this combination [ 84 ].

Dapsone is administered orally at 50–100 mg/day to both adult and pediatric patients. The treatment was generally well-tolerated. However, mild hemolysis occurs in most patients, whereas significant hemolysis is less common. Therefore, clinicians should monitor for the potential development of methemoglobin [ 85 - 89 ].

Mycophenolate mofetil is administered orally at 500–2,000 mg/day to adult patients. Serious adverse events include diarrhea, neutropenia, anemia, and viral infections. Prolonged drug use increases the risk for malignancy and progressive multifocal leukoencephalopathy. It has also been associated with pure red aplasia. It is a teratogen that should not be prescribed during pregnancy or lactation [ 90 - 92 ].

Vinca alkaloids can be used as treatment options for ITP. Patients can achieve a rapid response at 7 days with vincristine (1–2 mg per dose once weekly for 2–4 wk in adult patients) or vinblastine (10 mg per dose once weekly for 1–3 wk in adult patients). Almost all patients experience adverse events, such as vincristine neuropathy, vinblastine-associated bone marrow suppression, constipation, hyponatremia, and infusion site vesication. Vinca alkaloids are contraindicated in pregnancy and lactation [ 93 - 95 ].

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.